Kymera Therapeutics Statistics
Share Statistics
Kymera Therapeutics has 65.12M
shares outstanding. The number of shares has increased by 5.84%
in one year.
| Shares Outstanding | 65.12M |
| Shares Change (YoY) | 5.84% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 94.22% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 262 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 7M, so 10.74% of the outstanding
shares have been sold short.
| Short Interest | 7M |
| Short % of Shares Out | 10.74% |
| Short % of Float | 13.57% |
| Short Ratio (days to cover) | 10.74 |
Valuation Ratios
The PE ratio is -13.49 and the forward
PE ratio is -10.98.
Kymera Therapeutics's PEG ratio is
-0.74.
| PE Ratio | -13.49 |
| Forward PE | -10.98 |
| PS Ratio | 64.14 |
| Forward PS | 4.9 |
| PB Ratio | 3.61 |
| P/FCF Ratio | -14.56 |
| PEG Ratio | -0.74 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Kymera Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.53,
with a Debt / Equity ratio of 0.11.
| Current Ratio | 7.53 |
| Quick Ratio | 7.53 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.41 |
| Debt / FCF | -0.42 |
| Interest Coverage | -1050.74 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $226,307.69 |
| Profits Per Employee | $-1,076,240.38 |
| Employee Count | 208 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 36.44% in the
last 52 weeks. The beta is 2.19, so Kymera Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.19 |
| 52-Week Price Change | 36.44% |
| 50-Day Moving Average | 29.62 |
| 200-Day Moving Average | 39.47 |
| Relative Strength Index (RSI) | 74.96 |
| Average Volume (20 Days) | 801,785 |
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of 47.07M
and earned -223.86M
in profits. Earnings per share was -2.98.
| Revenue | 47.07M |
| Gross Profit | 39.7M |
| Operating Income | -261.63M |
| Net Income | -223.86M |
| EBITDA | -216.24M |
| EBIT | -223.61M |
| Earnings Per Share (EPS) | -2.98 |
Full Income StatementBalance Sheet
The company has 120.26M in cash and 87.76M in
debt, giving a net cash position of 32.49M.
| Cash & Cash Equivalents | 120.26M |
| Total Debt | 87.76M |
| Net Cash | 32.49M |
| Retained Earnings | -754.61M |
| Total Assets | 918.31M |
| Working Capital | 441.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -194.5M
and capital expenditures -12.84M, giving a free cash flow of -207.34M.
| Operating Cash Flow | -194.5M |
| Capital Expenditures | -12.84M |
| Free Cash Flow | -207.34M |
| FCF Per Share | -2.76 |
Full Cash Flow StatementMargins
Gross margin is 84.34%, with operating and profit margins of -555.82% and -475.57%.
| Gross Margin | 84.34% |
| Operating Margin | -555.82% |
| Pretax Margin | -475.57% |
| Profit Margin | -475.57% |
| EBITDA Margin | -459.37% |
| EBIT Margin | -555.82% |
| FCF Margin | -440.47% |
